Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
2024年2月6日 - 6:41AM
ビジネスワイヤ(英語)
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or
“Revelation”), a life sciences company that is focused on
harnessing the power of trained immunity for the prevention and
treatment of disease, today announced the closing on February 5,
2024 of its previously announced public offering of 128,470 shares
of its common stock and 1,236,530 pre-funded warrants to purchase
shares of common stock, together with warrants to purchase up to
2,730,000 shares of its common stock at an offering price to the
public of $4.53 per share and associated warrant, or $4.5299 per
pre-funded warrant and associated warrant. The warrants have an
exercise price of $4.53 per share, are exercisable upon issuance,
and will expire five years following the date of issuance.
Roth Capital Partners acted as sole placement agent for the
offering.
The gross proceeds to the Company from the offering are
approximately $6.2 million, before deducting the placement agent’s
fees and other offering expenses payable by Revelation. The Company
intends to use the net proceeds from this offering to further the
development of GEM-SSI, GEM-AKI and GEM-CKD including (i) a
combined Phase 1a clinical study for GEM-SSI and GEM-AKI, (ii) a
Phase 1b clinical study for GEM-SSI for the prevention of surgical
site infection in colorectal surgery, (iii) a Phase 1b clinical
study for GEM-AKI for the prevention and treatment of AKI due to
cardiac surgery, (iv) necessary preclinical work for GEM-CKD, (v)
continue to develop other products and therapies, and (vi) fund
working capital and general corporate purposes using any remaining
amounts.
The securities described above are being offered pursuant to a
registration statement on Form S-1 (File No. 333-276232), as
amended, that was declared effective by the U.S. Securities and
Exchange Commission (“SEC”), on January 31, 2024. The offering is
being made solely by means of a prospectus. Copies of the
accompanying prospectus relating to and describing the terms of the
offering may be obtained, when available, at the SEC’s website at
www.sec.gov or by contacting Roth Capital Partners, LLC, 888 San
Clemente Drive, Suite 400, Newport Beach, CA 92660 or by email at
rothecm@roth.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or other jurisdiction in which such an offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or other jurisdiction.
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. is a life sciences company focused
on harnessing the power of trained immunity for the prevention and
treatment of disease using its proprietary formulation, Gemini.
Revelation has multiple ongoing programs to evaluate Gemini,
including GEMINI-SSI as a prevention for hospital acquired
infection, GEMINI-AKI as a prevention for acute kidney injury, and
GEMINI-CKD for the treatment of chronic kidney disease.
For more information on Revelation, please visit
www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These forward-looking statements are generally
identified by the words "anticipate," "believe," "expect,"
"estimate," "plan," "outlook," and "project" and other similar
expressions. We caution investors that forward-looking statements
are based on management’s expectations and are only predictions or
statements of current expectations and involve known and unknown
risks, uncertainties and other factors that may cause actual
results to be materially different from those anticipated by the
forward-looking statements. Revelation cautions readers not to
place undue reliance on any such forward-looking statements, which
speak only as of the date they were made. The following factors,
among others, could cause actual results to differ materially from
those described in these forward-looking statements: the ability of
Revelation to meet its financial and strategic goals, due to, among
other things, competition; the ability of Revelation to grow and
manage growth profitability and retain its key employees; the
possibility that Revelation may be adversely affected by other
economic, business, and/or competitive factors; risks relating to
the successful development of Revelation’s product candidates; the
ability to successfully complete planned clinical studies of its
product candidates; the risk that we may not fully enroll our
clinical studies or enrollment will take longer than expected;
risks relating to the occurrence of adverse safety events and/or
unexpected concerns that may arise from data or analysis from our
clinical studies; changes in applicable laws or regulations;
expected initiation of the clinical studies, the timing of clinical
data; the outcome of the clinical data, including whether the
results of such study is positive or whether it can be replicated;
the outcome of data collected, including whether the results of
such data and/or correlation can be replicated; the timing, costs,
conduct and outcome of our other clinical studies; the anticipated
treatment of future clinical data by the FDA, the EMA or other
regulatory authorities, including whether such data will be
sufficient for approval; the success of future development
activities for its product candidates; potential indications for
which product candidates may be developed; the ability of
Revelation to maintain the listing of its securities on NASDAQ; the
expected duration over which Revelation’s balances will fund its
operations; and other risks and uncertainties described herein, as
well as those risks and uncertainties discussed from time to time
in other reports and other public filings with the SEC by
Revelation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240205917010/en/
Sandra Vedrick Vice President, Investor Relations & Human
Resources Revelation Biosciences Inc. Email:
svedrick@revbiosciences.com
and
Chester Zygmont, III Chief Financial Officer Revelation
Biosciences Inc. Email: czygmont@revbiosciences.com
Revelation Biosciences (NASDAQ:REVB)
過去 株価チャート
から 11 2024 まで 12 2024
Revelation Biosciences (NASDAQ:REVB)
過去 株価チャート
から 12 2023 まで 12 2024